Covid19 research hub

I4V-MC-KHAB: A Multicenter, Open-Label, Pharmacokinetic and Safety Study of Baricitinib in Pediatric Patients From 1 Year to Less Than 18 Years Old Hospitalized With COVID-19

This study is looking at a medicine called Baricitinib for children aged 1 to 18 who are in hospital with COVID-19. We want to see how the body handles the medicine and if it's safe for them. This is a later stage of testing to confirm its effects.